Ubiquitin-conjugating enzyme 2C (UBE2C), which is highly expressed in most CRC patients, not only promotes the growth rate of CRC cells, but also enhances resistance to CPT-11 (Cacciola et al. 2016). This evidence concerns the gene UBE2C and colorectal carcinoma.